Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Open angle glaucoma~Exclusion Criteria:~* Uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular disorders.~* Functionally significant visual field loss, including severe nerve fiber bundle defects.~* Prior glaucoma surgery.~* Uncontrolled systemic disease, pregnant females or those planning a pregnancy.~* Other ocular status conditions, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Travoprost Intraocular Implant, high elution (Type: EXPERIMENTAL): This implant will be surgically implanted and elute travoprost, a prostaglandin.
- Travoprost Intraocular Implant, low elution (Type: EXPERIMENTAL): This implant will be surgically implanted and elute travoprost, a prostaglandin.
- Timolol Maleate Ophthalmic Solution, 0.5% (Type: ACTIVE_COMPARATOR): Timolol, a beta blocker, will be dosed twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).